Clinical effect of multicenter multidisciplinary treatment in children with renal malignant tumors.
- Author:
Ze-Xi YIN
1
;
Xiang-Ling HE
1
;
Jun HE
;
Xin TIAN
1
;
Cheng-Guang ZHU
1
;
Ke-Ke CHEN
1
;
Run-Ying ZOU
1
;
Ya-Lan YOU
1
;
Xin-Ping JIANG
;
Wen-Fang TANG
1
;
Min-Hui ZENG
1
;
Zhi-Jun HUANG
1
;
An-Qi YAO
1
Author Information
1. Department of Hematology and Oncology, First Affiliated Hospital of Hunan Normal University/Children's Medical Center of Hunan Provincial People's Hospital, Changsha 410005, China.
- Publication Type:Multicenter Study
- MeSH:
Child;
Family;
Humans;
Kidney Neoplasms/therapy*;
Progression-Free Survival;
Retrospective Studies
- From:
Chinese Journal of Contemporary Pediatrics
2021;23(2):169-173
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To study the long-term clinical effect of multicenter multidisciplinary treatment (MDT) in children with renal malignant tumors.
METHODS:A retrospective analysis was performed on the medical data of 55 children with renal malignant tumors who were diagnosed and treated with MDT in 3 hospitals in Hunan Province from January 2015 to January 2020, with GD-WT-2010 and CCCG-WT-2016 for treatment regimens. A Kaplan-Meier survival analysis was used to analyze the survival of the children.
RESULTS:Of the 55 children, 10 had stage I tumor, 14 had stage Ⅱ tumor, 22 had stage Ⅲ tumor, 7 had stage IV tumor, and 2 had stage V tumor. As for pathological type, 47 had FH type and 8 had UFH type. All children underwent complete tumor resection. Of the 55 children, 14 (25%) received preoperative chemotherapy. All children, except 1 child with renal cell carcinoma, received postoperative chemotherapy. Among the 31 children with indication for radiotherapy, 21 (68%) received postoperative radiotherapy. One child died of postoperative metastasis. The incidence rate of FH-type myelosuppression was 94.4%, and the incidence rate of UFH-type myelosuppression was 100%. The median follow-up time was 21 months and the median survival time was 26 months for all children, with an overall survival rate of 98% and an event-free survival rate of 95%.
CONCLUSIONS:Multicenter MDT has the advantages of high success rate of operation and good therapeutic effect of chemotherapy in the treatment of children with renal malignant tumors, with myelosuppression as the most common side effects, and radiotherapy is safe and effective with few adverse events. Therefore, MDT has good feasibility, safety, and economy.
